175 related articles for article (PubMed ID: 38590799)
21. IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma.
Weber R; Riester Z; Hüser L; Sticht C; Siebenmorgen A; Groth C; Hu X; Altevogt P; Utikal JS; Umansky V
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788238
[TBL] [Abstract][Full Text] [Related]
22. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
Clavijo PE; Friedman J; Robbins Y; Moore EC; Smith E; Zauderer M; Evans EE; Allen CT
Cancer Immunol Res; 2019 Feb; 7(2):282-291. PubMed ID: 30514791
[TBL] [Abstract][Full Text] [Related]
23. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract][Full Text] [Related]
24. Global stability and parameter analysis reinforce therapeutic targets of PD-L1-PD-1 and MDSCs for glioblastoma.
Anderson HG; Takacs GP; Harris DC; Kuang Y; Harrison JK; Stepien TL
J Math Biol; 2023 Dec; 88(1):10. PubMed ID: 38099947
[TBL] [Abstract][Full Text] [Related]
25. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
[TBL] [Abstract][Full Text] [Related]
26. Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
Park JA; Wang L; Cheung NV
J Hematol Oncol; 2021 Sep; 14(1):142. PubMed ID: 34496935
[TBL] [Abstract][Full Text] [Related]
27. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
[TBL] [Abstract][Full Text] [Related]
28. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
29. CCR5
Blattner C; Fleming V; Weber R; Himmelhan B; Altevogt P; Gebhardt C; Schulze TJ; Razon H; Hawila E; Wildbaum G; Utikal J; Karin N; Umansky V
Cancer Res; 2018 Jan; 78(1):157-167. PubMed ID: 29089297
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
31. PI3K-CCL2-CCR2-MDSCs axis: A potential pathway for tumor Clostridia-promoted CD 8
Ma WJ; Li ZH; Wu ZR; Liu F; Wang JK; Shi YJ; Jin YW; Li FY
Neoplasia; 2023 Sep; 43():100920. PubMed ID: 37515847
[TBL] [Abstract][Full Text] [Related]
32. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
[TBL] [Abstract][Full Text] [Related]
33. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
[TBL] [Abstract][Full Text] [Related]
34. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
35. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
36. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
37. Monocytic myeloid-derived suppressor cells home to tumor-draining lymph nodes via CCR2 and locally modulate the immune response.
Lahmar Q; Schouppe E; Morias Y; Van Overmeire E; De Baetselier P; Movahedi K; Laoui D; Sarukhan A; Van Ginderachter JA
Cell Immunol; 2021 Apr; 362():104296. PubMed ID: 33556903
[TBL] [Abstract][Full Text] [Related]
38. Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer.
Yang L; Wang B; Qin J; Zhou H; Majumdar APN; Peng F
Immunopharmacol Immunotoxicol; 2018 Feb; 40(1):91-97. PubMed ID: 29303012
[TBL] [Abstract][Full Text] [Related]
39. 5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy-resistant lung tumor.
Mathew AA; Zakkariya ZT; Ashokan A; Manohar M; Keechilat P; Nair SV; Koyakutty M
Int Immunopharmacol; 2023 Jul; 120():110129. PubMed ID: 37201402
[TBL] [Abstract][Full Text] [Related]
40. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
